Ninerafaxstat in the Treatment of Diabetic Cardiomyopathy and Nonobstructive Hypertrophic Cardiomyopathy.
Ninerafaxstat 在糖尿病性心肌病和非阻塞性肥厚型心肌病的治療中。
Cardiol Rev 2024-08-28
Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy.
SGLT2抑制劑在糖尿病合併非梗阻性肥厚型心肌病患者中的療效。
Am J Cardiol 2023-03-10
Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial).
非糖尿病患者在前壁心肌梗塞後,達帕格列酮對心臟功能的影響 - DACAMI(一項隨機對照臨床試驗)。
Int J Cardiol 2023-06-25
Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
人工心臟組織中模擬的肥厚型心肌病功能障礙,並且可透過鈉葡萄糖共同轉運蛋白2抑制劑改善。
Cardiovasc Res 2024-04-13
Effect of dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: An observational study.
非缺血性擴張型心肌病患者接受達帕格酮對左心室結構和功能的影響:一項觀察性研究。
Medicine (Baltimore) 2024-04-01
Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications.
從糖尿病到心臟衰竭:探索途徑和潛在藥物的心臟基質。
Biomedicines 2024-06-27
Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes.
Dapagliflozin 和 sacubitril 對於急性心肌梗塞後心臟衰竭及第二型糖尿病患者心肌微灌注的影響。
World J Clin Cases 2024-08-07